Vaccination continues to have a major impact on the health of humans and animals.
Furthermore, vaccination of animals is proving to be effective in reducing transmission
to humans. Understanding linkages between innate and adaptive immunity are improving
formulations of new, as well as existing, vaccines, making them more effective.
Vaccination has saved more lives than many other therapeutic interventions combined.
Prominent examples are smallpox and polio, where prior to immunization, millions of
people died annually. Indeed, the World Health Organization estimates that vaccination
has prevented paralysis in over eight million people since polio eradication programs
began in 1988. These are just two examples of many diseases that have been effectively
controlled by vaccination and thus have saved millions of lives. As a result, our
children today are protected from diseases, such as measles, pertussis, tetanus and
diphtheria to name a few. However, even with such overwhelming statistics, a strong
anti-vaccine lobby exists to dissuade parents from vaccinating their children. This
is both wrong and ill-informed placing individuals and communities at risk. These
individuals benefit from being surrounded by vaccinated children by an effect commonly
referred to as herd immunity. Unfortunately, this is being ignored by the strong lobby
groups, who base their rhetoric on a few very selected falsehoods and ignore the benefits
of immunization. The classical falsehood is that vaccines cause autism. This has been
disproved many times but still gets brought up by the anti-vaccine lobby groups as
well as the popular press. Thus, communicating the benefits of immunization to the
broad public represents an important challenge for all of us.
Another big challenge to vaccination today is that most vaccines are delivered by
needle injection. This often results in local mild reactions and these minor adverse
events are being used as a reason to dissuade individuals not to vaccinate their children.
Indeed, in our society, all forms of ‘preventive medicine' are looked upon less favorably
than therapies. Many of our therapeutic drugs cause significantly greater adverse
reactions than vaccines. However, they are accepted because they are treatments. Anti-cancer
drugs are one of the best examples, which may have many side effects. The reason for
this dichotomy is that our society is much less accepting of preventative medicine
versus therapeutic approaches to disease management. If the focus continues to favor
expensive therapeutics over economic preventative medicine, escalating costs of health
care will bankrupt society.
Important areas for the use of vaccines are the emerging zoonotic infections that
can cross the species barrier and that are transmitted from humans to animal, or vice
versa. Examples include the recent pandemic influenza, severe acute respiratory syndrome
and avian influenza, to name a few. In fact, over 70% of new emerging and re-emerging
diseases are zoonotic in nature. Since drugs do not exist to control these diseases,
vaccines are the best choices for disease control. Indeed, we should place more emphasis
on immunizing the animal species concerned to reduce the chance of transmission to
humans. Similarly, contamination of food and food products with disease causing organisms,
such as Salmonella, Escherichia coli or Campylobacter, are responsible for billions
of dollars in losses every year. The recent Listeria outbreak in Europe caused over
40 deaths and millions of euros in direct and indirect costs, highlighting the importance
of food safety and the need for vaccines that can enhance the safety of our food and
food products (food safety vaccines). An example of such vaccines is the development
of an E. coli 0157:H7 vaccine for cattle to reduce shedding of the bacterium into
the environment and contamination of meat and meat products, thereby reducing the
chance of human infection.
1
Thus, one can control infection rates in humans by immunizing animals. Similarly,
immunization of humans can protect animals since diseases can move from humans to
animals, as recently shown for influenza virus H1N1 transmission from humans to animals,
2
providing support for the ‘One World One Health' concept.
3
The majority of vaccines used today have been developed by conventional methods and
fall into two categories, live vaccines and killed vaccines.
In the case of live vaccines, the pathogen is passaged in culture multiple times resulting
in specific mutations that render the pathogen less virulent than field strains of
the agent. These vaccines are then administered to individuals; the agent replicates
and induces a full array of immune responses leading to protective immunity upon subsequent
exposure to the pathogen.
4,5
In the case of killed vaccines, the pathogen is chemically inactivated to prevent
its replication but not so dramatically as to interfere with the antigenic components
of the pathogen, which then induce a more restricted immune response, although often
sufficient to prevent disease. This later group of vaccines are generally mixed with
immune stimulants (adjuvants) to enhance the immunity to the killed pathogen. Killed
vaccines can induce a mild reaction in some vaccinated individuals since they are
often administered by needle injection.
To reduce side effects of vaccines, and improve efficacy, the focus over the last
few years has been on developing novel vaccines, delivery systems and adjuvants. The
merging of molecular biology and immunology has dramatically enhanced our ability
to improve vaccine efficacy and safety. For example, by identifying and deleting virulence
genes in a virus or a bacterium, one can reduce the ability of the agent to cause
disease. Back mutations are almost impossible to occur, which make these vaccines
extremely safe. More importantly, such vaccines can be delivered by the natural route
and induce a wide array of immune responses generated by infection leading to solid
immunity. For example, if delivered mucosally, they induce both mucosal and systemic
immunity, which is critical, since most pathogens enter by the mucosal surfaces. This
not only reduces the disease in the vaccinated individual but also dramatically reduces
the quantity of pathogens secreted into the environment should this vaccinated individual
get infected.
6
This approach has been further improved by using molecular biology to produce vectored
vaccines or killed vaccines. For most pathogens, only a few (1–5) specific antigenic
components are required for induction of protective immunity. Thus, in the case of
bacteria, the other 1000+ proteins are irrelevant to induction of protective immunity
and indeed, some of these proteins may actually be detrimental to protective immunity.
Using what is called reverse vaccinology,
7
one can screen for these protective antigens and insert them into a vector—examples
include the yellow fever virus or pox virus and adenovirus vectors for HIV vaccination
8,9,10
or introduce them into a bacterium or yeast to produce large quantities of killed
antigens in bioreactors. These so-called subunit antigens cannot replicate, they are
safe, and since the response is specific for the selected antigens only, they allow
us to distinguish between vaccinated and infected individuals and animals, so called
marker or differentiate infected from vaccinated animals vaccines. In fact, global
trade of animals and animal products is largely regulated by the policies around the
absence of antibodies to specific infectious diseases.
11
Unfortunately, most subunit vaccines are not very immunogenic and need to be formulated
with immune stimulants (adjuvants). The majority of killed vaccines in humans were
formulated with alum. The regulatory agencies favor alum as an adjuvant because of
extensive experience with it. Unfortunately, it produces a skewed immune response
that favors systemic antibody production and gives little mucosal or cellular immunity.
In many cases, cellular and mucosal immunity is required to control an infection;
thus, there is room for improvement of these vaccines. Indeed, much can be learned
from the development of vaccines for animals and many different adjuvants and delivery
strategies have been successfully used for decades. The development of safe and effective
adjuvants for humans is a hot topic in vaccine research, and as a result we are starting
to see licensure of novel adjuvants such as MF59, AS01-AS03, ISOMS, etc.
Due to a better understanding of the immune system, we are now able to tailor the
quality as well as the magnitude of the immune response. If one then combines adjuvants
with appropriate formulations that can be introduced at mucosal sites, it provides
the best chance of inducing mucosal immunity with a safe killed vaccine without needle
injection.
12,13,14
This is critical in resource constraint environments where expensive needles are difficult
to obtain. Furthermore, such an approach helps to reduce the number of immunizations
required to provide protective immunity, something that is urgently needed in developing
countries where access to vaccines is limited, as well as lowering the cost by reducing
the amount of antigen needed (antigen spearing).
15
The best example occurred following the outbreak of H1N1 influenza where the ability
to produce large quantities of vaccine was limited due to time constraints between
the appearance of the virus and need for vaccination of the population. Thus, if one
can expand the number of individuals immunized by 10-fold, that would dramatically
improve the control of the disease.
Based on the recent advances in understanding immune responses and identifying antigens
involved in inducing protection from a number of infectious agents combined with the
willingness of regulatory agencies to begin licensing combination, adjuvants gives
us confidence that we will be able to develop new vaccines to new agents and also
improve existing vaccines that can even be safer than our vaccines used today. In
this way, all members of society will benefit.